Peter Voorhees, MD, Atrium Health

Frontline Triplet Therapies in Multiple Myeloma

July 17th 2020

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 20th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 19th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. Voorhees on the Effectiveness of Idecabtagene Vicleucel in Multiple Myeloma

May 2nd 2020

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.

Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

February 5th 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Dr. Voorhees on Updated Depth of Response in GRIFFIN Trial in Multiple Myeloma

January 23rd 2020

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Dr. Voorhees on the ELOQUENT-3 Trial in Late Relapsed/Refractory Multiple Myeloma

September 12th 2019

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Dr. Voorhees Discusses Safety Run-in of Daratumumab in Myeloma

January 12th 2019

Peter Voorhees, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, discusses the safety run-in of the Griffin study looking at daratumumab in myeloma.

Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

April 28th 2018

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Dr. Voorhees on Managing TRAEs for Patients With Multiple Myeloma

September 6th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

July 12th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

Dr. Voorhees on Triplet Regimen in Multiple Myeloma

February 3rd 2016

Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.

Dr. Voorhees on the Future Treatment Paradigm for Myeloma

August 11th 2015

Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.